AlloVir, Inc. ALVR NASDAQ

AlloVir, Inc. (ALVR) reported total assets of $121.74M and total liabilities of $42.92M for fiscal year 2025, resulting in total equity of $78.81M.

The company held $117.98M in cash and short-term investments. Total debt stood at $1.45M, with net debt of $-96.61M. The Debt-to-Equity (D/E) ratio was 0.02 (conservative).

Current ratio is 12.23, indicating strong short-term liquidity. Interest coverage is -32x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (28/100) — Total assets $121.74M and equity $78.81M support the company's competitive scale

Overall SharesGrow Score: 44/100 with 1/7 criteria passed.

MRUS

Merus N.V.

$90.00

+0.00%

CRNX

Crinetics Pharmaceuticals, Inc.

$39.77

+0.05%

STOK

Stoke Therapeutics, Inc.

$35.54

-0.89%

AGIO

Agios Pharmaceuticals, Inc.

$34.45

+3.45%

MLYS

Mineralys Therapeutics, Inc.

$30.42

+11.35%

ANAB

AnaptysBio, Inc.

$67.89

-3.32%

INBX

Inhibrx Biosciences, Inc.

$83.60

+0.49%

CGEM

Cullinan Oncology, Inc.

$14.95

+4.18%